Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre

BJU International

Volumn 111, Issue 8, 2013, Pages

  Ali El Dein, Bedeir ^a   Sooriakumaran, Prasanna ^b   Trinh, Quoc Dien ^c   Barakat, Tamer S ^a   Nabeeh, Adel ^a   Ibrahiem, El Housseiny I ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c Vattikuti Urology Institute   (United States)

Author keywords

bacillus Calmette Gu rin (BCG); non muscle invasive bladder cancer (NMIBC); predictive index; prognostic factors; T1; Ta

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; VISCUM ALBUM EXTRACT;

ACCURACY; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CALIBRATION; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; COHORT ANALYSIS; CYSTECTOMY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NOMOGRAM; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; SEX; SINGLE DRUG DOSE; TUMOR VOLUME; UNIVARIATE ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CYSTECTOMY; DISEASE PROGRESSION; EGYPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84878273588     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12026     Document Type: Article

References (24)

1. Epstein JI, Amin MB, Reuter VR, Mostofi FK,. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-1448 (Pubitemid 28550639)
2. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr,. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 22-29 (Pubitemid 19028816)
3. Parmar MK, Freedman LS, Hargreave TB, Tolley DA,. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989; 142: 284-288 (Pubitemid 19197097)
4. Reading J, Hall RR, Parmar MK,. The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice. Br J Urol 1995; 75: 604-607
5. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-477
6. Ali-El-Dein B, Sarhan O, Hinev A, Ibrahiem EI, Nabeeh A, Ghoneim MA,. Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index. BJU Int 2003; 92: 393-399 (Pubitemid 37100517)
7. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-314
8. Van Rhijn BWG, Zuiverloon TCW, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010; 58: 433-441
9. Hernández V, De La Peña E, Martin MD, Blázquez C, Diaz FJ, Llorente C,. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol 2011; 29: 409-414
10. Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol 2011; 60: 423-430
11. Ali-El-Dein B, Baraka TS, Nabeeh A, Ibrahiem E-H,. Validation of Sylvester predictive model in cases of progression on top of non-muscle invasive bladder TCC. Eur Urol Suppl 2010; 9: 324 (abstract 1036)
12. Hemanek PS, Sobin LH, eds. UICC-International Union Against Cancer. TNM Classification of Malignant Tumors, 4th edn. Heidelberg, Germany: Springer-Verlag, 1987
13. Mostofi K, Sobin LH,. Histologic Typing of Urinary Bladder Tumors. International Histological Classification of Tumors. Geneva, Switzerland: World Health Organization, 1973
14. Dalesio O, Schulman CC, Sylvester R, et al. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 1983; 129: 730-733 (Pubitemid 13080873)
15. Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM,. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group. Br J Urol 1994; 73: 403-408 (Pubitemid 24133562)
16. Allard P, Bernard P, Fradet Y, Têtu B,. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81: 692-698 (Pubitemid 28316632)
17. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodríguez J,. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73-78
18. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD,. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004; 93: 485-490
19. Han RF, Pan JG,. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67: 1216-1223 (Pubitemid 43818066)
20. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-256
21. Gontero P, Bohle A, Malmstrom PU, et al. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57: 410-429
22. Sylvester RJ, van der Meijden AP, Lamm DL,. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-1970
23. Andius P, Johansson SL, Holmäng S,. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007; 70: 758-762 (Pubitemid 350030224)
24. Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA,. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle invasive bladder cancer. Eur Urol 2011; 60: 713-720